HUP9904669A3 - Therapeutic applications of t-bam(cd40l)technology to treat diseases involving smooth muscle cells - Google Patents
Therapeutic applications of t-bam(cd40l)technology to treat diseases involving smooth muscle cellsInfo
- Publication number
- HUP9904669A3 HUP9904669A3 HU9904669A HUP9904669A HUP9904669A3 HU P9904669 A3 HUP9904669 A3 HU P9904669A3 HU 9904669 A HU9904669 A HU 9904669A HU P9904669 A HUP9904669 A HU P9904669A HU P9904669 A3 HUP9904669 A3 HU P9904669A3
- Authority
- HU
- Hungary
- Prior art keywords
- cd40l
- bam
- technology
- smooth muscle
- muscle cells
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67773096A | 1996-07-08 | 1996-07-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9904669A2 HUP9904669A2 (en) | 2000-05-28 |
| HUP9904669A3 true HUP9904669A3 (en) | 2001-06-28 |
Family
ID=24719894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9904669A HUP9904669A3 (en) | 1996-07-08 | 1997-07-03 | Therapeutic applications of t-bam(cd40l)technology to treat diseases involving smooth muscle cells |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20030219437A1 (en) |
| EP (1) | EP0956030A4 (en) |
| JP (1) | JP2000515507A (en) |
| CN (1) | CN1242809C (en) |
| AU (1) | AU731299B2 (en) |
| BG (1) | BG63489B1 (en) |
| BR (1) | BR9710264A (en) |
| CA (1) | CA2259962C (en) |
| CZ (1) | CZ297300B6 (en) |
| EA (1) | EA004401B1 (en) |
| EE (1) | EE9900010A (en) |
| HU (1) | HUP9904669A3 (en) |
| IL (1) | IL127884A0 (en) |
| IS (1) | IS4935A (en) |
| NO (1) | NO990019L (en) |
| NZ (1) | NZ333602A (en) |
| PL (1) | PL188408B1 (en) |
| SK (1) | SK499A3 (en) |
| TR (1) | TR199900029T2 (en) |
| WO (1) | WO1998001145A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0110779A (en) | 2000-05-12 | 2005-01-11 | Beth Israel Hospital | Compositions and methods for acquiring immune suppression |
| US20020173053A1 (en) * | 2001-04-27 | 2002-11-21 | Bassam Damaj | Multiple simultaneous antigen detection by immunohistochemistry |
| ES2263984T3 (en) * | 2002-06-28 | 2006-12-16 | Domantis Limited | DOUBLE-SPECIFIC LINKS WITH AN INCREASED SERIOUS MIDDLE LIFE. |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| UY32802A (en) * | 2009-07-23 | 2011-01-31 | Provimi Holding B V | COMPOSITIONS TO REDUCE GASTROINTESTINAL METANOGENESIS IN RUMINANTS |
| TW201741337A (en) * | 2016-05-13 | 2017-12-01 | 麥迪紐有限責任公司 | CD40L-Fc fusion polypeptides and methods of use thereof |
| KR102019033B1 (en) * | 2016-11-11 | 2019-09-06 | 다이노나(주) | Antibody specifically binding to CD40 and use thereof |
| US11793854B2 (en) | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5474771A (en) * | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
| CA2089229C (en) * | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
| US6340459B1 (en) * | 1995-12-01 | 2002-01-22 | The Trustees Of Columbia University In The City Of New York | Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients |
| US6822070B2 (en) * | 1996-03-11 | 2004-11-23 | David Baltimore | Truncated CRAF1 inhibits CD40 signaling |
-
1997
- 1997-07-03 CZ CZ0002699A patent/CZ297300B6/en not_active IP Right Cessation
- 1997-07-03 TR TR1999/00029T patent/TR199900029T2/en unknown
- 1997-07-03 HU HU9904669A patent/HUP9904669A3/en not_active Application Discontinuation
- 1997-07-03 PL PL97331104A patent/PL188408B1/en not_active IP Right Cessation
- 1997-07-03 CN CNB971971749A patent/CN1242809C/en not_active Expired - Fee Related
- 1997-07-03 EA EA199900091A patent/EA004401B1/en not_active IP Right Cessation
- 1997-07-03 JP JP10505404A patent/JP2000515507A/en active Pending
- 1997-07-03 EE EEP199900010A patent/EE9900010A/en unknown
- 1997-07-03 SK SK4-99A patent/SK499A3/en unknown
- 1997-07-03 AU AU42292/97A patent/AU731299B2/en not_active Ceased
- 1997-07-03 IL IL12788497A patent/IL127884A0/en unknown
- 1997-07-03 EP EP97940539A patent/EP0956030A4/en not_active Withdrawn
- 1997-07-03 WO PCT/US1997/012925 patent/WO1998001145A1/en active IP Right Grant
- 1997-07-03 CA CA002259962A patent/CA2259962C/en not_active Expired - Fee Related
- 1997-07-03 NZ NZ333602A patent/NZ333602A/en unknown
- 1997-07-03 BR BR9710264A patent/BR9710264A/en not_active Application Discontinuation
-
1998
- 1998-12-23 IS IS4935A patent/IS4935A/en unknown
-
1999
- 1999-01-04 NO NO990019A patent/NO990019L/en not_active Application Discontinuation
- 1999-02-04 BG BG103148A patent/BG63489B1/en unknown
-
2002
- 2002-11-15 US US10/298,508 patent/US20030219437A1/en not_active Abandoned
-
2007
- 2007-01-25 US US11/698,692 patent/US20080050369A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TR199900029T2 (en) | 1999-04-21 |
| NO990019L (en) | 1999-03-08 |
| CA2259962A1 (en) | 1998-01-15 |
| AU4229297A (en) | 1998-02-02 |
| AU731299B2 (en) | 2001-03-29 |
| BR9710264A (en) | 1999-08-10 |
| BG103148A (en) | 1999-10-29 |
| NZ333602A (en) | 2000-06-23 |
| PL188408B1 (en) | 2005-01-31 |
| CN1227494A (en) | 1999-09-01 |
| EP0956030A4 (en) | 2001-11-28 |
| CZ2699A3 (en) | 1999-05-12 |
| IL127884A0 (en) | 1999-10-28 |
| EA004401B1 (en) | 2004-04-29 |
| NO990019D0 (en) | 1999-01-04 |
| US20030219437A1 (en) | 2003-11-27 |
| WO1998001145A1 (en) | 1998-01-15 |
| BG63489B1 (en) | 2002-03-29 |
| CN1242809C (en) | 2006-02-22 |
| CA2259962C (en) | 2002-01-22 |
| EP0956030A1 (en) | 1999-11-17 |
| HUP9904669A2 (en) | 2000-05-28 |
| CZ297300B6 (en) | 2006-11-15 |
| US20080050369A1 (en) | 2008-02-28 |
| IS4935A (en) | 1998-12-23 |
| SK499A3 (en) | 1999-08-06 |
| EA199900091A1 (en) | 1999-08-26 |
| EE9900010A (en) | 1999-06-15 |
| JP2000515507A (en) | 2000-11-21 |
| PL331104A1 (en) | 1999-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6649996A (en) | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease | |
| ZA9810122B (en) | Treatment of T-helper cell type 2 mediated immune diseases | |
| PL322464A1 (en) | Stimulation of biuological tissue by use of optical energy | |
| AU1805499A (en) | Method and apparatus for delivery of therapeutic agents to the heart | |
| EP0752885A4 (en) | Therapeutic inhibitor of vascular smooth muscle cells | |
| NZ501069A (en) | Monoesters of probucol for the treatment of cardiovascular and inflammatory disease | |
| AU9197898A (en) | Resilient wrist support and therapeutic hand exerciser and method of manufacture | |
| HK1009939A1 (en) | Medicament for treating cardiac inflammatory diseases | |
| AU3118699A (en) | Apparatus and method for therapeutic treatment of low back pain | |
| PL323797A1 (en) | Application of bisulphonates to prevent bone tissue loss associated with immunosuppressive therapy | |
| AU5106596A (en) | Therapy apparatus for the functional electromyostimulation of smooth muscle cells | |
| EP0734723A4 (en) | Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis | |
| HUP0002683A3 (en) | Compositions and methods for enhancing delivery of therapeutic agents to cells | |
| AU7566098A (en) | Methods and apparatus for portable delivery of electrical physical therapy mo dalities to a patient | |
| HUP9904669A3 (en) | Therapeutic applications of t-bam(cd40l)technology to treat diseases involving smooth muscle cells | |
| PL339836A1 (en) | Phtalazine compounds and therapeutic agents suitable to treat erection disorders | |
| HUP9802423A3 (en) | Combined therapeutical treatment of hyperproliferative diseases | |
| HUP0001263A3 (en) | Methods of therapeutic administration of anti-cd4ol compounds | |
| PL336760A1 (en) | Treatment of skin diseases | |
| ZA96314B (en) | Use of sertraline to treat cancer patients | |
| HUP9802834A3 (en) | Preparations for the treatment of t cell mediated autoimmune diseases | |
| ZA969147B (en) | Application of the gax protein to the treatment of cancer | |
| EP1150669A4 (en) | L-arginine based formulations for treating diseases and methods of using same | |
| EP1009433A4 (en) | Therapeutic composition and method of treatment | |
| AU6388396A (en) | Electromagnetic therapeutic treatment device and methods of using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Change of name, address |
Owner name: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CIT, US Free format text: FORMER OWNER(S): BIOGEN, INCORPORATED, US Owner name: BIOGEN IDEC MA, INC., US Free format text: FORMER OWNER(S): BIOGEN, INCORPORATED, US |
|
| FC4A | Lapse of provisional application due to refusal |